Stratasys launches all-in-one J5 MediJet medical 3D printer

The MediJet printer is designed for anatomical models, surgical guides and medical tools using sterilizable and biocompatible materials

Stratasys Limited company (NASDAQ stock code:SSYS) A medical 3D printer was launched today, which sets a new standard for healthcare providers and medical device companies by combining multiple applications in one system. The Stratasys J5 MediJet™ 3D printer has multiple materials and multi-color capabilities, enabling users to use approved third-party 510k clear segmentation software to create highly detailed 3D anatomical models and drilling and cutting guides. The guides and models are proven to be sterilizable and biocompatible, and the printer is economical and compact, suitable for small laboratory spaces.

This press release features multimedia. View the full version here: https://www.businesswire.com/news/home/20210603006012/en/

The J5 MediJet 3D printer is the latest product of Stratasys J5 Series™ printers and J5 DentaJet™ and J55™. In operation, it has a patented rotating build platform and a fixed print head. This is designed to maximize reliability and simplify maintenance. The system also provides more output with a smaller footprint. Compared with other 3D printers, the MediJet 3D printer is 30% faster and has a simple workflow, including automatic tray arrangement, correction, and support for the latest 3MF file format to simplify the connection with third-party segmentation and design software.

The new printer supports DraftWhite™ materials, suitable for affordable single-material applications, and a new range of flexible, rigid colors and transparent materials. The multi-material function supports a wide range of medical modeling applications in a platform suitable for office, thereby reducing outsourcing costs or the need for multiple printers.

“For small and medium-sized hospitals, we can access models and guides using a medical-specific 3D printer suitable for offices and at an affordable price, while ensuring easy disinfection, so you can bring the models directly into the operating room,” said Osnat Philipp, Stratasys’ Vice President of Healthcare . “We also believe that the J5 MediJet printer can help medical device companies bring new innovations to the market faster by providing models for medical device benchmarking and product demonstrations, and use the models to show the actual pathology that the device will treat.”

Everything is on a certified systemThe J5 MediJet printer has passed the certification of the leading 510K clear DICOM segmentation software package and can be used for clinical diagnosis. In addition, it can print biocompatible materials that are certified for limited contact with tissues and bones, permanent contact with intact skin (ISO 10993), and breathing gas pathways in healthcare applications (ISO 18562). MediJet models can also be sterilized using steam, gamma, and EtO methods specific to printing materials.

The J5 MediJet material and hardware manufacturing base has obtained ISO 13485 certification for the design and manufacturing of medical devices.

Printers and materials are now available.Learn more about the clinical and economic value of medical 3D printing on Stratasys website.

Stratasys It is leading the global transition to additive manufacturing, providing innovative 3D printing solutions for industries such as aerospace, automotive, consumer products, and healthcare. Through smart connected 3D printers, polymer materials, software ecosystems and on-demand parts, Stratasys solutions have a competitive advantage at every stage of the product value chain. The world’s leading organizations turned to Stratasys to transform product designs, increase manufacturing and supply chain flexibility, and improve patient care.

To learn more about Stratasys, please visit www.stratasys.com, Stratasys Blog, Twitter, LinkedIn, Or FacebookStratasys reserves the right to use any of the above social media platforms (including company websites) to share important non-public information in accordance with SEC regulations FD. To the extent necessary and required by applicable laws, Stratasys will also include such information in its public disclosure documents.

Stratasys, PolyJet, J5, J5 series, DraftWhite and MediJet are trademarks or registered trademarks of Stratasys Limited company and/or its affiliates. All other trademarks are the property of their respective owners, and Stratasys assumes no responsibility for the selection, performance, or use of these non-Stratasys products.

Notes on forward-looking statements

The statements in this press release regarding Stratasys’ beliefs about the benefits of consumers using J5 MediJet are forward-looking statements and reflect management’s current expectations and beliefs. These forward-looking statements are based on current information, which, by its nature, may undergo rapid or even sudden changes. Due to the risks and uncertainties associated with Stratasys’ business, actual results may differ materially from those predicted or implied in these forward-looking statements.These risks and uncertainties include, but are not limited to: our success in launching new products that gain market share or improving products and solutions; the overall growth of the 3D printing market; the duration of the global COVID-19 pandemic, if The pandemic may continue to affect the operations, financial condition and cash flow of us and our customers and suppliers in a material and adverse way; the impact of potential changes in the prices or profit margins of the products we sell or the services we provide, including Due to the shift to products or services with lower profit margins; the impact of competition and new technologies; due to the impairment of additional goodwill or other intangible assets, we may need to impose potential further charges on the income; after we successfully complete the new business and technology , Product or service acquisition or investment success; potential changes in our management and board of directors; global market, political and economic conditions, especially in the countries in which we operate (including the impact of the coronavirus on our operations, Risks related to the impact of supply chain, liquidity, cash flow and customer orders; related to litigation and regulatory procedures; risks related to others’ infringement of our intellectual property rights or our infringement of others’ intellectual property rights; we are maintaining liquidity and maintaining liquidity for our operations The degree of success in financing and capital requirements; the impact of tax regulations on our performance, operations and financial conditions; and the title “Risk Factors” in the latest Form 20-F annual report submitted by Stratasys to the US Securities and Exchange Commission (SEC) on March 1 Other risk factors listed below^Yingshi, 2021. Readers are urged to carefully review and consider the various disclosures made in our 2020 annual report and other reports we submit or provide to the SEC. These reports are intended to provide stakeholders with risks and factors that may affect our business Recommendations, financial status, business performance and prospects. Any guidance and other forward-looking statements provided in this press release are made on the date of this press release, and Stratasys assumes no obligation to publicly update or revise any forward-looking statements, whether due to new information, future events, or otherwise, Unless required by law.

Pay attention to editing. If you publish reader contact information, please use:

• United States +800-801-6491

• Europe/Middle East/Africa+49-7229-7772-0

• Asia Pacific +852 3944-8888

View the source version on businesswire.com: https://www.businesswire.com/news/home/20210603006012/en/